公司新闻

Atom Bioscience to Update Clinical Development of New Drug to Treat Gout at BIO International Convention, June 13 – 16, 2022, San Diego, CA
PRESS RELEASE Atom Bioscience to Update Clinical Development of New Drug to Treat Gout at BIO International...
On Gout Awareness Day, Let’s Put the Myths to Rest
PRESS RELEASE On Gout Awareness Day, Let’s Put the Myths to Rest Genetic abnormalities are the real cause...
新元素医药宣布,其治疗慢性痛风创新药ABP-671的2a期临床显示出极佳结果
初步数据表明,新元素医药的化合物可以大幅度降低血尿酸水平,从而预防痛风发作,且不会产生现有药物类似的毒副作用。
Atom Bioscience to Present at BIO CEO & Investor Conference on February 14, 2022
Lead drug targets unmet medical need in chronic gout Provides significant serum uric acid reduction in...
Atom Bioscience to Present at Biotech Showcase January 10-12, 2022
Lead drug targets unmet medical need in chronic gout Provides significant efficacy without toxic side...
江苏新元素医药完成超3亿元人民币C轮融资
江苏新元素医药科技有限公司近日完成超3亿元人民币的C轮融资,本轮融资由熙诚金睿和高特佳领投,倚锋资本、元禾控股和乾道集团跟投,原股东凯泰资本、丽珠医药、红杉中国继续追加投资。
新元素医药完成约3000万美元B轮融资
新元素医药是一家以代谢性疾病和抗肿瘤创新药研发为核心的生物医药公司,其痛风创新药具有良好的疗效和显著的安全性优势,有望为全球痛风患者带来福音。
新元素医药治疗痛风创新药通过美国IND申请,并在美开展I期临床研究
江苏新元素医药科技有限公司近日宣布, 该公司抗痛风创新药物ABP-671于2018年9月向美国FDA提交了新药临床研究(IND)申请,现已获得FDA临床批件,并在美国开展I期临床试验。

行业动态

BioWorld: Atom Bioscience Planning Phase III Gout Trial After Encouraging Mid-Stage Readout
BioSpace: Atom Bioscience Announces Positive Phase 2a Results For Investigational New Drug to Treat Chronic Gout
Healio.com: 'Horribly mismanaged': Debate over gout treatment rages as cases surge
Gout and Heart Disease: Why You're at Increased Risk
Physicians Weekly: Analyzing the Genetics of Hyperuricemia & Gout in Post-Partum Racial/Ethnic Groups